Investigation into VYNE Therapeutics Inc. for possible breaches of fiduciary duty in transaction with Yarrow Bioscience.
In Milwaukee on December 18, 2025, The Ademi Firm announced an investigation into VYNE (Nasdaq: VYNE) regarding potential breaches of fiduciary duty and legal violations related to its recent deal with Yarrow Bioscience. Individuals interested in participating in the investigation and gaining further information can access details by clicking the provided link.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments